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Abstract
A rare coding variant (rs72824905, p.P522R) conferring protection against Alzheimer’s disease (AD) was identified in the 
gene encoding the enzyme phospholipase-C-γ2 (PLCG2) that is highly expressed in microglia. To explore the protective 
nature of this variant, we employed latent process linear mixed models to examine the association of p.P522R with lon-
gitudinal cognitive decline in 3595 MCI patients, and in 10,097 individuals from population-based studies. Furthermore, 
association with CSF levels of  pTau181, total tau, and Aβ1-42 was assessed in 1261 MCI patients. We found that MCI patients 
who carried the p.P522R variant showed a slower rate of cognitive decline compared to non-carriers and that this effect was 
mediated by lower  pTau181 levels in CSF. The effect size of the association of p.P522R with the cognitive decline and  pTau181 
was similar to that of APOE-ε4, the strongest genetic risk factor for AD. Interestingly, the protective effect of p.P522R was 
more pronounced in MCI patients with low Aβ1-42 levels suggesting a role of PLCG2 in the response to amyloid pathology. In 
line with this hypothesis, we observed no protective effect of the PLCG2 variant on the cognitive decline in population-based 
studies probably due to the lower prevalence of amyloid positivity in these samples compared to MCI patients. Concerning 
the potential biological underpinnings, we identified a network of co-expressed proteins connecting PLCG2 to APOE and 
TREM2 using unsupervised co-regulatory network analysis. The network was highly enriched for the complement cascade 
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and genes differentially expressed in disease-associated microglia. Our data show that p.P522R in PLCG2 reduces AD disease 
progression by mitigating tau pathology in the presence of amyloid pathology and, as a consequence, maintains cognitive 
function. Targeting the enzyme PLCG2 might provide a new therapeutic approach for treating AD.
Keywords Alzheimer’s disease · PLCG2 · Phospholipase C gamma 2 · Cognitive decline · Mild cognitive impairment
Introduction
Alzheimer’s disease (AD) is highly heritable and the most 
common cause of neurodegenerative dementias. The dis-
covery of mutations in amyloid precursor protein (APP), 
Presenilin1 and Presenilin2 (PSEN1/2) causing rare familial 
AD laid an important foundation for the ‘amyloid cascade 
hypothesis’, postulating that the aggregation of amyloid 
is causative for AD and triggers downstream pathological 
events such as the formation of tau pathology [38]. The 
importance of amyloid for the development of the more 
common, sporadic form of AD has recently been empha-
sized by two large genome-wide association studies (GWAS) 
[33, 41]. Besides amyloid, GWAS studies suggest additional 
causative molecular pathways, including immune system 
processes [33, 35, 41]. Interestingly, it has been suggested 
that pathways supported by genetic evidence might provide 
entry points for drug development with a better chance of 
clinical success [37, 55]. Unfortunately, for most GWAS-
identified loci, the variants responsible for the AD-associ-
ation are unknown, which hampers their translation into a 
clear functional consequence.
In 2017, we and others identified a specific rare non-
synonymous coding variant (rs72824905, p.P522R) in the 
gene encoding the enzyme phospholipase-C-γ2 (PLCG2) 
that confers protection against the susceptibility to AD [68]. 
This association has been replicated in multiple independ-
ent samples from different populations [10, 13, 78]. PLCG2 
is an enzyme mainly expressed in immune cells including 
microglia which are involved in innate immunity [47, 78]. 
PLCG2 is related to autoimmune diseases and involved in 
the activation of platelets in response to amyloid [8, 52, 
66]. From a functional perspective, p.P522R induces a 
slight increase in PLCG2 activity [47]. Thus, therapeutic 
strategies similarly modulating PLCG2 activity as p.P522R 
may offer a new treatment option for common sporadic AD 
forms. To achieve this latter aim, we need first to understand 
the biological mechanisms linking p.P522R in PLCG2 to 
the pathophysiological processes of AD. Importantly, van 
der Lee and colleagues [78] suggested that the p.P522R 
might also have a protective effect on other neurodegenera-
tive dementias [i.e., Dementia with Lewy Body (DLB) and 
frontotemporal dementia (FTD)] as well as a positive effect 
on longevity. However, it is unclear whether these protec-
tive effects result from an attenuated protein accumulation 
process that may be accelerated by microglia activation [4, 
5, 28, 70, 72, 79, 85] in carriers of the mutated PLCG2 gene, 
or whether the response to accumulated protein aggregates 
is different, which is the suggested modus operandi for other 
AD-associated genes like TREM2 [34].
To understand the boundary conditions and mechanisms 
of p.P522R effects, we examined its association with cog-
nitive decline in patients with mild cognitive impairment 
(MCI) and population-based studies. We also analyzed the 
effect of p.P522R on cerebrospinal fluid (CSF) biomark-
ers levels amyloid-beta 1-42 (Aβ1-42), total tau (tTau) pro-
tein, and phosphorylated tau  (pTau181) protein as well as 
their interactions in patients with MCI. We also investi-
gated potential biological underpinnings for the effect of 
PLCG2 within the context of AD pathology. We focused 
our analysis on the identification of a link between PLCG2 
and the known functional relationship between APOE and 
TREM2. While research identified APOE as a ligand for 
TREM2 [67, 84] and PLCG2 as an important element of the 
TREM2 downstream signaling cascade [54], a link between 
PLCG2 and APOE is currently missing. Consequently, we 
conducted an unsupervised analysis of trans-co-regulatory 
network analysis to identify a biological pathway shared 
between APOE and the TREM2–PLCG2-signaling cascade.
Methods
Study cohorts
The design, recruitment, and diagnostic procedures are 
described in detail in the supplementary text 1, online 
resource. A flowchart of the participant recruitment and 
their assignment to outcome-specific analyses is presented 
in Fig. 1. All participants included in the analyses were older 
than 50 years, since the focus of our study was the effect of 
p.P522R in late life.
Longitudinal cognitive decline was analyzed in 3595 
MCI patients. These patients were derived from four mem-
ory clinic cohorts, namely the Amsterdam dementia cohort 
(ADC), the German dementia competence network (DCN), 
the Spanish Fundacio ACE (FACE), and the Alzheimer’s 
disease neuroimaging initiative (ADNI) cohort that was 
launched as public–private partnership led by Michael 
Weiner with the aim to establish measurements of disease 
progression in MCI and AD (see supplementary text 1, 
online resource for full description). Also, MCI patients 
1027Acta Neuropathologica (2020) 139:1025–1044 
1 3
from the prospective, general practitioner-registry-based 
German study on aging, cognition, and dementia (AgeCoDe) 
were included. Participants of the AgeCoDe cohort were all 
non-demented at baseline. Among those, the MCI patients 
were identified by a standardized diagnostic procedure at 
each visit and included in this analysis.
10,097 participants from the Three-City Study (3C) and 
the Longitudinal Aging Study Amsterdam (LASA), as well 
as all participants from the AgeCoDe study, were included 
for the analysis of the cognitive decline in population-based 
samples regardless of MCI or dementia diagnoses.
To analyze the effect of p.P522R on proxy measures of 
amyloid and tau pathology in the CSF, levels of Aβ1-42, 
 pTau181, and tTau protein were analyzed. CSF data were 
collected from 1,261 MCI from the DCN, ADC and ANDI 
cohort as well as from the memory clinic of the University 
Hospital of Bonn (UHB) and processed at different centers 
(supplementary text 4, online resource).
Genotyping
In all samples, DNA was extracted using standard proce-
dures. In all cohorts except LASA and ADNI, p.P522R 
was directly genotyped using the MassARRAY (3C cohort, 
Agena Bioscience), custom content using the Infinium-
global-screening-array-24-v1 (ADC cohort, Illumina), or 
a TaqMan custom design genotyping assay (other cohorts, 
Thermo Fisher Scientific), respectively. In LASA, p.P522R 
genotypes were derived from imputation based on the 
Infinium-global-screening-array-24-v1(Illumina, imputa-
tion quality: R2 = 0.89) or the AXIOM-NL (Affymetrix, 
imputation quality: R2 = 0.93) array. In ADNI, three dif-
ferent platforms [i.e., Illumina Human610-Quad BeadChip 
(imputation quality: R2 = 0.87), HumanOmniExpress Bead-
Chip (imputation quality: R2 = 0.83), and Illumina Omni 
2.5 M (imputation quality: R2 = 0.93)] were used for deriving 
p.P522R genotypes from imputed values. In case multiple 
platforms were used for genotyping the same individual, 
we retained p.P522R imputations with the highest geno-
type probability. All procedures are described in detail in 
supplementary text 2, online resource. For a fraction of the 
samples included in the analysis, GWAS data were available. 
In these samples, all individuals of non-European ancestry 
were discarded and the presence of population stratification 
was excluded by visually inspecting a plot of the first two 
principal components (PCs) of the GWAS data (supplemen-
tary Fig. 1a–g, online resource). No evidence for population 
stratification was found during visual inspection. In line with 
that, adjustment for PCs in those samples with GWAS data 
did not change the effects observed for p.P522R (supplemen-
tary text 3). For this reason, PCs were not used to adjust the 
analysis maximizing thereby the data set for analysis and 
thus increasing the statistical power.
CSF collection and biomarker measurement
CSF levels of Aβ1-42,  pTau181, and tTau were measured using 
commercial ELISA immunoassays. Samples were quanti-
fied in different laboratories (CSF samples from Erlangen, 
Bonn, Amsterdam, and the ADNI cohort, see Fig. 1) using 
different methods described in supplementary text 4.1, 
online resource. For the present analysis, CSF from different 
Fig. 1  Study design
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cohorts was harmonized using the method described by 
Zhou and colleagues [89] (supplementary text 4.2, online 
resource).
Neuropsychological assessments
In all cohorts, the Mini-Mental State Examination (MMSE) 
was used as this measure of global cognition is sensitive to 
change in patients with MCI [59] and available in all cohorts. 
In the population-based studies, the MMSE might show ceil-
ing effects. Therefore, additional measurements were used 
for the cognitive function: the 3C cohort also measured epi-
sodic memory using the Benton visual retention test, the 
LASA cohort used the Dutch version of the Adult Verbal 
Learning Task, and the AgeCoDe cohort used the CERAD 
word list learning task with delayed recall. Besides, verbal 
fluency was assessed in the 3C and AgeCoDe study using the 
Isaac set test and the CERAD animal fluency task, respec-
tively. References and further descriptions for all tests are 
given in supplementary text 5, online resource.
Statistical analysis
Statistical analyses were conducted in R version 3.4.4 [58] 
and Mplus version 7.31 [50]. References to all utilized soft-
ware are provided in supplementary Table 1, online resource. 
More detailed descriptions of the used methods are provided 
below and in supplementary text 6, online resource. All p 
values < 0.05 (two-sided) were considered significant.
Analysis of cognitive decline
The analysis of the effect of p.P522R on longitudinal cogni-
tive decline was performed using latent process linear mixed 
models [56] (supplementary text 6.1, online resource) as 
implemented in the R package LCMM [57]. These mod-
els jointly estimate a latent process representing the true 
change of cognition over time and a link function that relates 
this process to the observed cognitive measurements. This 
link function takes into account the unequal interval scaling 
that commonly occurs for cognitive tests and may introduce 
bias [56] by modeling a monotone but possibly non-linear 
relationship between the latent process and the outcome. 
Modeling of the link function also accounted for the skewed 
distribution of the MMSE indicated ceiling effects in some 
MCI patients. Moreover, residuals derived from the stand-
ard linear mixed model showed deviations from normality 
which were adjusted by including the appropriate link func-
tion. Potential non-linear decline trajectories were assessed 
using polynomial order of time. The most appropriate link 
function and polynomial of time were chosen according to 
the lowest Bayesian information criterion (BIC). Statistical 
significance of the effect of p.P522R on the decline was 
assessed using multivariate Wald tests.
For the analysis of MCI patients, median-centered time 
from MCI diagnosis was used as the time scale to approxi-
mate disease progression after cognitive symptom onset. 
In the AgeCoDe cohort, the baseline for our analysis was 
defined as the first visit where MCI criteria were met and 
only subsequent observations were considered as follow-
up assessments. In a sensitivity analysis, the follow-up time 
was restricted up to 6 years to rule out that a possible effect 
of p.P522R was artificially induced by only a few observa-
tions with long follow-up. An integrative data analysis was 
performed by pooling data from all memory clinic cohorts 
to maximize the number of p.P522R carriers as recom-
mended for rare predictors [11]. Also, stratified analyses 
in each cohort were performed. The relationship between 
p.P522R and APOE-ε4 was investigated by examining the 
interaction effect on the cognitive decline between the two 
genotypes. In addition, effect sizes on cognitive change of 
p.P522R in the absence and presence of APOE-ε4 were com-
pared with the effect of APOE-ε4 alone. Due to potential 
non-linear decline, effects were calculated at multiple time 
points on the scale of the latent process, standardized by the 
predicted variation at the last time point (supplementary text 
6.2, online resource).
For the analysis of the effect of p.P522R in three popula-
tion-based cohorts, median-centered age at assessment was 
used as the time scale of the linear mixed models represent-
ing general age-related cognitive change. Herein, analyses 
were performed separately for each cohort.
All analyses in all samples were adjusted for age at base-
line, as well as gender, education (i.e., dichotomous vari-
able indicating participation in secondary education), and 
APOE-ε4 status (supplementary text 6.5, online resource). 
In the pooled analysis of MCI patients from memory clinic 
cohorts, analyses were additionally adjusted for cohort. Fur-
thermore, center was included as an additional covariate in 
the 3C study and the genotyping platform was used as a 
covariate in LASA. In the case of significant associations, 
analyses were repeated without adjustment to examine the 
sensitivity of the results to covariate selection. Missing data 
in the cognitive outcomes were handled using maximum-
likelihood estimation [15], so that no participants had to be 
excluded due to drop-out.
Analysis of CSF biomarkers
For CSF analysis, continuous harmonized CSF biomarker 
data were log-transformed. Robust regression analysis was 
used to minimize the influence of outlying observations in 
the data by applying a down-weighting algorithm [40].
AD biomarkers were analyzed in a joint regression model 
using data from all CSF samples to maximize the number 
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of available p.P522R carriers. Also, stratified analyses were 
performed in the samples from the three European mem-
ory clinic cohorts (DCN, ADC, and UHB) and the ADNI 
cohort. All regression analyses were controlled for age, gen-
der, the origin of the CSF samples, and the presence of at 
least one APOE-ε4 allele (see supplementary text 6.5, online 
resource). We adjusted p values from tests of multiple out-
comes (i.e., three different AD biomarkers) by applying the 
Bonferroni–Holm correction.
To explore whether p.P522R affects the interplay of 
AD biomarkers, four AD biomarker categories were con-
structed as described by Jack and colleagues [29] based on 
laboratory-specific cut-offs. These categories were derived: 
AD  (Abeta1-42 positive and  pTau181 positive, irrespective of 
tTau), AD pathologic change  (Abeta1-42 positive and  pTau181 
negative, irrespective of tTau), non-AD pathologic change 
 (Abeta1-42 negative and  pTau181 positive and/or tTau posi-
tive), and no pathologic change (all three biomarkers nega-
tive). These categories were used as the outcome in a multi-
nomial regression model with AD as the reference category 
and Bonferroni–Holm correction for multiple testing (i.e., 
comparison of four biomarker categories).
In addition, a varying coefficient generalized additive 
model [82] (supplementary text 6.3, online resource) was 
used to test whether the effect of p.P522R on continuous 
 pTau181 and tTau levels differs across different Aβ1-42 levels. 
Thin plate regression splines [81] were used to allow for 
non-linear, potentially sigmoid relationships between AD 
biomarkers as proposed by Jack and colleagues [30]. Poste-
rior simulation with simultaneous confidence intervals was 
used to identify those levels of CSF Aβ1-42 at which p.P522R 
show its strongest effects.
All analyses in CSF samples were adjusted for age, gen-
der, CSF samples, and APOE-ε4 status (supplementary text 
6.5, online resource). In a sensitivity analysis, all analyses 
were repeated without adjustment for covariates.
Mediation analysis using structural equation 
models
To evaluate whether or not the associations of p.P522R with 
CSF biomarkers underlie the association of p.P522R with 
cognitive decline, a mediation analysis was conducted using 
structural equation modeling in Mplus version 7.31 [50]. 
Herein, 1052 MCI patients from the DCN, ADC, and ADNI 
cohorts were included only if they had CSF AD biomark-
ers as well as longitudinal MMSE assessments available. 
To assess mediation, an indirect effect of p.P522R on the 
cognitive change in the MMSE over 4 years via Aβ1-42 and 
tTau were estimated, as well as interaction effects between 
p.P522R, and Aβ1-42 or  pTau181. Analyses were repeated 
using  pTau181 instead of tTau in the models. Additional 
details are provided in supplementary text 6.4, online 
resource.
Co‑regulatory network analysis
The GeneFriends tool was used to generate an unsupervised 
co-expression gene map based on 4164 Human Microarray 
data sets containing 26,113 experimental conditions and 
19,080 genes. We decided to use the microarrays data avail-
able in GeneFriends tool, because the number of experi-
mental conditions available was larger and better annotated 
compared to the RNA-sequencing data available in the same 
tool. Further description of the microarray methods is pro-
vided elsewhere [77]. Of note, loci around the target genes 
might co-express due to the existence of common regional 
co-regulation motifs. Cis-co-regulated genes were deleted 
from the respective list by removing all transcripts located 
200 kb around PLCG2, APOE, and TREM2 loci. Hence, 
only highly trans-co-regulated and positively co-expressed 
genes that are collectively upregulated were selected for fur-
ther analysis (co-expression value > 0.5). Next, the WebGe-
stalt tool [45] was used to identify potential enrichments in 
identified co-regulated gene lists using overrepresentation 
enrichment analyses of Gene Ontology non-redundant bio-
logical process in humans. Furthermore, genes co-expressed 
with PLCG2 were tested for enrichment of shared co-expres-
sion with APOE and TREM2 using Fisher’s exact test (sup-
plementary text 6.6, online resource). Genes co-expressed 
in all three candidate genes were selected for additional 
enrichment analyses using STRING [75] and WebGestalt. 
Finally, this shared gene set was tested for enrichment of 
genes differentially expressed in cell-type-specific biomate-
rials derived from brain, i.e., microglia of AD patients [49] 
as well as microglia derived from the 5XFAD AD mouse 
model [39] and the hMAPT-P301S model for tauopathies 
[19] (supplementary text 6.6, online resource).
Results
The p.P522R variant is associated with slower 
cognitive decline in MCI patients
Due to the low frequency of the rare variant, it is unlikely 
to detect statistically significant effects in the individ-
ual cohorts. We, therefore, pooled data from all cohorts 
(Table 1) in a joint analysis in a first step. Here, carriers 
of the p.P522R variant (n = 61) showed a slower cognitive 
decline than non-carriers (χ2(2) = 7.83, p = 0.020, Fig. 2a; 
supplementary Table 2, online resource). Importantly, analy-
ses stratified for cohort demonstrated a highly consistent pro-
tective effect of p.P522R in each of the samples (Fig. 2b–e, 
supplementary Fig. 2, and supplementary Table 3, online 
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resource). This consistency was further confirmed by a 
non-significant interaction between p.P522R and cohorts 
concerning the effect on the cognitive decline (χ2(8) = 3.55, 
p = 0.895). Sensitivity analyses showed no change in the 
association without adjustment for covariates (χ2(2) = 8.95, 
p = 0.011) or using a restricted follow-up interval of 6 years 
(χ2 (2) = 6.58, p = 0.037, supplementary Table 2, online 
resource). 
In the same cohorts, the APOE-ε4 allele was, as 
expected, associated with accelerated cognitive decline 
(χ2 (2) = 138.33, p = 9.27 × 10–37, supplementary Table 2, 
online resource), but there was no statistically significant 
interaction between APOE-ε4 and p.P522R (χ2 (2) = 2.87, 
p = 0.238, supplementary table 4, online resource). The 
absence of a significant interaction may arise from limited 
statistical power due to the small number of carriers for both 
the p.P522R and the APOE-ε4 alleles (n = 23). However, 
Fig. 2  Effect of p.P522R on the cognitive decline in 3,595 MCI 
patients. a Predicted trajectories of cognitive decline for p.P522R 
carrier and non-carrier in the pooled sample of all MCI patients. b 
Predicted trajectories of cognitive decline for p.P522R carrier and 
non-carrier in the Fundacio ACE (FACE) cohort. c Predicted tra-
jectories of cognitive decline for p.P522R carrier and non-carrier 
in the German study on aging, cognition, and dementia (AgeCoDe) 
cohort. d Predicted trajectories of cognitive decline for p.P522R car-
rier and non-carrier in the Dementia competence network (DCN) 
cohort. e Predicted trajectories of cognitive decline for p.P522R car-
rier and non-carrier in the ADNI cohort. Predicted trajectories for 
the Amsterdam dementia cohort (ADC) are displayed in supplemen-
tary figure  1, online resource due to the unreasonably low number 
of p.P522R carriers with sufficient follow-up. f Effect of p.P522R 
and APOE-ε4 on the cognitive change from baseline in the MMSE 
derived from a linear mixed model with a latent process including an 
interaction term between APOE-ε4 and p.P522R. Differences on the 
latent process scale between APOE-ε4 carrier and non-carrier who do 
not carry the pP522R variant were derived to assess the effect size 
of APOE-ε4 (red arrow in Fig.  2f and red dots in Fig.  2g, h). The 
difference between p.P522R carrier and non-carrier in the absence 
(magenta arrows in Fig. 2f and magenta dots in Fig. 2g) and the pres-
ence of APOE-ε4 (green arrows in fig. 2f and green dots in Fig. 2h) 
were calculated, as well. g The effect size of the association of not 
carrying any APOE-ε4 allele (red dots) and p.P522R in the presence 
of APOE-ε4 (green dots) with the cognitive change at different time 
points. Effect sizes are displayed on the scale of the latent process of 
the mixed model standardized by the expected variance of the latent 
process at the last time point considered (see supplementary text 
6.2, online resource). h The effect size of the association of not car-
rying any APOE-ε4 allele (red dots) and p.P522R in the absence of 
APOE-ε4 (magenta dots) with the cognitive change at different time 
points. Effect sizes are displayed on the scale of the latent process of 
the mixed model standardized by the expected variance of the latent 
process at the last time point considered (see supplementary text 6.2, 
online resource)
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the protective effect of p.P522R and the detrimental effect 
of APOE-ε4 on the cognitive change from baseline were 
similar in magnitude though in opposite directions (Fig. 2f). 
To directly compare the protective effect of PLCG2 with 
that of APOE, we expressed the APOE effect on cognitive 
decline in protective terms, i.e., cognitive changes when 
APOE-ε4 is absent (Fig. 2g, h). This analysis suggested that 
the protective effect of p.P522R is as strong as the detrimen-
tal APOE-ε4 effect during the first 6 years of follow-up, but 
this effect decreased at later follow-ups (Fig. 2f, g). This 
raises the possibility that p.P522R may initially counteract, 
at least in part, the detrimental effect of the APOE-ε4 allele 
on cognitive function and could delay deterioration in MCI 
patients for several years. We also found that the protec-
tive effect on cognitive change associated with p.P522R in 
APOE-ε4 non-carriers was similar to the reduced cognitive 
change observed in the absence of APOE-ε4 alone, espe-
cially at later stages of the cognitive trajectory (Fig. 2h).
Age‑related cognitive decline in population‑based 
samples is not associated with p.P522R
Given our observation in MCI and the previously reported 
effect on longevity [78], we sought to explore whether the 
effect of p.P522R on cognitive decline can be also extended 
to the general population (Table 2). As expected from previ-
ous case–control studies [68, 78], the frequency of p.P522R 
in the population-based samples was significantly higher 
than in the sample of MCI patients from memory clinic 
cohorts (i.e., FACE, DCN, ADNI, and ADC) who are an 
at-risk population for dementia (χ2(1) = 10.02, p = 0.002). 
Importantly, the statistical difference found for this variant 
between the MCI samples and the population-based studies 
further support the protective effect of PLCG2. However, 
p.P522R did not modulate the cognitive decline in any of the 
neuropsychological tests explored in the population-based 
samples (supplementary table 5, supplementary Figs. 3–5, 
online resource).
p.P522R is associated with reduced levels of CSF 
 pTau181 and tTau
To examine the etiology underlying the protective effect of 
p.P522R, we analyzed AD-related CSF biomarkers in MCI 
patients (Table 3). Carriers of the p.P522R variant (n = 18) 
showed a reduction of  pTau181 (Est(SE) = −  0.12(0.05), 
p = 0.015, d = − 0.58) and tTau levels (Est(SE) = − 0.12 
(0.05), p = 0.017, d = − 0.57) in the pooled sample of all 
MCI patients. The association remained statistically sig-
nificant after Bonferroni–Holm correction for multiple 
testing (Fig. 3, supplementary table 6, online resource). In 
contrast, there was no association of p.P522R with Aβ1-42 
levels (Est(SE) = − 0.02(0.04), p = 0.686, d = − 0.10). The 
effect of p.P522R was consistent across MCI patients from 
both the European MCI cohorts (DCN, ADC, and UHB) 
and the ADNI cohort (Fig. 3). This was confirmed by non-
significant interactions between p.P522R and CSF samples 
(supplementary table 7, online resource). Sensitivity analy-
ses suggested that unadjusted analysis led to a similar pattern 
of results (supplementary table 6, online resource).
Again, the effect sizes of p.P522R and APOE-ε4 on 
 pTau181 in the pooled MCI patients were similar, but 
in opposite directions (p.P522R: d = − 0.58, APOE-ε4: 
d = 0.56; supplementary table 8, online resource). We did 
not observe a statistically significant interaction between 
APOE-ε4 and p.P522R regarding any CSF biomarker (sup-
plementary table 9, online resource). The lack of interac-
tion may, again, follow the same power issue derived from 
Table 2  Characteristics of population-based samples included in the analysis of the cognitive decline
High education was operationalized as participation in secondary education
MMSE mini-mental state examination, n(%) number of individuals and percent within group, m mean, SD standard deviation
AgeCoDe 3 City study LASA
p.P522R carrier p.P522R non-carrier p.P522R carrier p.P522R non-carrier p.P522R carrier p.P522R non-carrier
Sample size (n (% of 
total sample))
49 (2.5%) 1918 (97.5%) 127 (2.2%) 5760 (97.8%) 56 (2.5%) 2187 (97.5%)
Age (m (SD)) 79.71 (3.64) 79.56 (3.51) 73.98 (5.22) 74.22 (5.46) 63.47 (6.39) 64.79 (7.63)
Female gender (n (%)) 32 (65.3%) 1245 (64.9%) 81 (63.8%) 349 (60.6%) 34 (60.7%) 1159 (53.0%)
High education (n (%)) 23 (46.9%) 848 (44.2%) 49 (38.6%) 3030 (52.6%) 45 (80.4%) 1619 (74.0%)
APOE-ε4 carrier (n 
(%))
10 (25.6%) 410 (21.4%) 33 (26.0%) 1188 (20.7%) 18 (29.6%) 638 (28.8%)
MMSE at baseline (m 
(SD))
26.88 (2.34) 27.41 (1.95) 27.34 (1.96) 27.37 (1.92) 27.64 (2.36) 27.88 (2.01)
Mean observation time 
(m (SD), in years)
6.05 (4.08) 6.21 (4.03) 5.40 (2.28) 5.34 (2.36) 11.72 (7.62) 10.73 (7.05)
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the small-sample size of carriers of both variants (n = 10). 
Notably, APOE-ε4 showed an effect on all CSF biomarkers, 
while p.P522R only had an effect on  pTau181 and tTau levels 
(supplementary table 8, online resource).
p.P522R exerts its strongest effect downstream 
of amyloid pathology
To further explore the role of p.P522R in AD, we exam-
ined the interplay of the same CSF biomarkers using the 
AD biomarker categories proposed by Jack and colleagues 
[29]. A multinomial regression model using the AD cat-
egory (Aβ1-42 and  pTau181 positive, n = 522) as a reference 
revealed that p.P522R was associated with the presence of 
AD pathologic change (Aβ1-42 positive,  pTau181 negative, 
OR(95% CI) 6.28(3.3, 11.9), p = 0.004, n = 279) but not with 
the presence of non-AD pathologic changes (Aβ1-42 negative, 
 pTau181 and/or tTau positive, OR(95% CI) 0.93(0.39, 2.24), 
p = 0.938, n = 129) or normal CSF biomarkers (all three bio-
markers negative, OR(95% CI) 1.81(0.86, 3.83), p = 0.425, 
n = 323). Noteworthy, the small number of amyloid-nega-
tive individuals might have limited the statistical power to 
detect an association of p.P522R with the presence of non-
AD pathological changes. Unadjusted analyses revealed the 
same results (supplementary table 10, online resource).
We also applied generalized additive models in the MCI 
data set to model the influence of the non-linear relationship 
of Aβ1-42 with  pTau181 and tTau in the CSF on the effect of 
p.P522R. We observed that the effect of p.P522R on  pTau181 
and tTau levels is significantly stronger when CSF levels 
of Aβ1-42 are low (i.e., more abnormal,  pTau181: p = 0.013, 
tTau: p = 0.020, Fig. 4a, b, supplementary table 11, online 
resource).
We then sought to conduct a mediation analysis in 1052 
MCI patients with both CSF biomarkers and longitudinal 
follow-up data using structural equation modeling (Fig. 4c, 
supplementary table 12, online resource). This analysis will 
allow establishing a link between the findings derived from 
the cognitive decline in MCI and those obtained from the 
CSF. This strategy revealed that the effect of p.P522R on the 
change in cognition from baseline over 4 years was mediated 
by  pTau181 (Est = 1.91, 95% CI 0.12, 4.11) but not by Aβ1-42 
(Est = 0.84, 95% CI − 0.54, 2.63, supplementary table 13, 
online resource). Noteworthy, we found a significant interac-
tion of p.P522R and Aβ1-42 levels on the cognitive decline 
(χ2(2) = 8.86, p = 0.012), indicating that the protective 
p.P522R variant is associated with a less pronounced cog-
nitive decline at more abnormal levels of Aβ1-42 (supplemen-
tary table 14, supplementary Fig. 6, online resource). This 
observation is in line with the findings obtained from the 
generalized additive model. There was no interaction effect 
between p.P522R and  pTau181 levels (χ2(2) = 0.68, p = 0.712) 
on the cognitive decline. The pattern of results was similar 
when tTau instead of  pTau181was used as a mediator. How-
ever, the effect of p.P522R on tTau (Est(SE) = − 0.22(0.12), 
p = 0.051) and the corresponding mediation effect on the 
cognitive change over 4 years (Est = 1.94, 95% CI = − 0.13, 
4.07) showed only a trend-level association (supplementary 
tables 12–14, online resource).
Conversely, we observed that the effect of APOE-ε4 on 
cognition change from baseline over 4 years is mediated 
by both, Aβ1-42 (Est = − 4.14, 95% CI − 5.67, − 2.57) and 
 pTau181 (Est = − 1.24, 95% CI − 2.15, − 0.56). However, 
there were no interaction effects between APOE-ε4 and the 
CSF levels of Aβ1-42 (χ2(2) = 1.29, p = 0.526) and  pTau181 
(χ2(2) = 2.531, p = 0.282) regarding the cognitive decline.
Fig. 3  Associations of p.P522R 
with CSF biomarkers of Alzhei-
mer’s disease (AD). Black dots 
and arrows represent Cohen’s 
d estimates and 95% confi-
dence interval, respectively. 
For Aβ1-42, negative Cohen’s d 
estimates indicate more pathol-
ogy. In the case of  pTau181 and 
tTau, positive Cohen’s d values 
represent more pathology. N(p.
P522R) number of p.P522R car-
rier, n(wt) number of p.P522R 
non-carrier, Aβ1-42 amyloid-beta 
1-42, pTau181 phosphorylated 
tau
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APOE shares a common co‑regulatory network 
with PLCG2 and TREM2
To explore the biological underpinnings of the interplay of 
APOE with PLCG2 and the membrane receptor TREM2, we 
searched for co-regulated genes and pathways. An unsuper-
vised search identified 2748 genes co-expressed with PLCG2 
showing enrichment of immune-related pathways (supplemen-
tary table 15, online resource). In our analysis, gene-specific 
networks of APOE and TREM2 were also highly enriched 
for immunological function (supplementary tables 16–17, 
online resource). Genes co-expressed with PLCG2 were sig-
nificantly enriched among those co-expressed with APOE 
(p = 7.49 × 10–34) or TREM2 (p = 1.37 × 10–33). Furthermore, 
PLCG2-related genes were disproportionally more likely to be 
co-expressed with both APOE and TREM2 (p = 3.76 × 10–16). 
Noteworthy, the shared gene set of 21 loci simultaneously 
co-regulated with APOE, TREM2, and PLCG2 (Fig. 5) is 
highly enriched for biological processes related to immune 
system processes including the complement cascade activation 
but also tissue remodeling (supplementary table 18, online 
resource). Furthermore, we also detected a correspondence 
between the identified network and microglial gene expres-
sion in the brain. Herein, we found enrichment for genes 
differential expressed in microglia from human AD patients 
(p = 3.57 × 10–12, [49]) as well as in microglia from mouse 
models of AD (p = 9.47 × 10–8, 5XFAD model [39]) or tauopa-
thies (p = 2.18 × 10–6, hMAPT-P301S model [19], supplemen-
tary table 19, online resource).
Fig. 4  Role of p.P522R in the interrelationship between amyloid 
pathology, neurodegeneration, and cognitive decline. a Predicted 
relationship between Aβ1-42 levels in CSF and  pTau181 levels in CSF 
for p.P522R carrier and non-carrier. Red shaded areas indicate sig-
nificant differences between p.P522R carrier and non-carrier. Sig-
nificance is based on the estimation of simultaneous confidence 
intervals that consider the statistical testing at multiple CSF levels. 
b Predicted relationship between Aβ1-42 levels in CSF total tau lev-
els in CSF for p.P522R carrier and non-carrier. Red shaded areas 
indicate significant differences between p.P522R carrier and non-
carrier. Significance is based on the estimation of simultaneous con-
fidence intervals that consider the statistical testing at multiple CSF 
levels. c Results from a structural equation model assessing whether 
the effect of p.P522R on the cognitive change in the normalized 
MMSE (range 0–100) is mediated  Abeta1-42 levels or  pTau181 levels 
in CSF. The model showed a good fit to the data (Model fit indices: 
RMSEA = 0.017, CFI = 0.996, SRMR = 0.060, see supplementary text 
6.4, online resource)
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Discussion
In this study, we provide the first evidence linking the pro-
tective effect of the p.P522R variant in PLCG2 with a slower 
cognitive decline in patients with MCI and reduced  pTau181 
and tTau levels. Interestingly, this effect seems to be down-
stream of Aβ1-42 pathology. Furthermore, we showed that 
PLCG2 shares a biological co-regulation network with the 
APOE and TREM2 that is enriched for complement cas-
cade processes and markers of disease-associated micro-
glia. Taken together, our findings strongly support a role of 
p.P522R in the physiological response to abnormally folded 
proteins, such as amyloid, and help to characterize the spe-
cific function of PLCG2 within the amyloid cascade.
To date, except for CLU and APOE, few of the identi-
fied genetic risk variants in case–control GWAS for AD 
have shown a consistent effect on disease progression in 
MCI patients [42]. Our study now adds to this list PLCG2 
as a strong protector of cognitive function at the MCI 
stage. This effect is mediated by reduced  pTau181 pathol-
ogy but not by Aβ1-42 pathology. Thus, the p.P522R vari-
ant ameliorates cognitive decline by acting downstream 
of amyloid accumulation, making this accumulation less 
detrimental. This hypothesis receives additional supports 
from the observation that p.P522R displays its strong-
est effect on tau pathology and cognitive decline when 
amyloid pathology is present. Recent research has further 
shown that tau pathology depends on Aβ1-42-evoked neu-
roinflammation [28]. Likewise, the neuronal protection 
conferred by p.P522R in AD may also operate in neuro-
degenerative diseases caused by the accumulation of other 
protein aggregates which trigger downstream damaging 
effects via neuroinflammation. Supporting this hypothesis, 
p.P522R in PLCG2 might also have a protective effect 
on DLB and FTD [78]. For all three diseases (i.e., AD, 
FTD, and DLB), a genetic overlap has been reported sug-
gesting shared pathogenic pathways which may include 
pathways related to PLCG2 [16, 24, 36, 64]. Furthermore, 
patients with DLB frequently show amyloid pathology 
[53] that contributes to fast disease progression and cog-
nitive impairment [1] suggesting that microglial reaction 
to amyloid pathology could mediate the protective role 
of p.P522R on both AD and DLB. In contrast, amyloid 
pathology is rarely observed in FTD indicating a slightly 
different mechanism. However, mutations in TREM2 have 
been consistently reported in FTD patients involving, 
thus, the TREM2 signal cascade in the pathological events 
occurring in FTD [20, 61]. Besides, functional studies in 
genes involved in FTD have shown that several of these 
genes can modulate microglia function either by increas-
ing production of neurotoxic factors and neuroinflamma-
tion, or by altering microglial phagocytosis and related 
degradation pathways [22]. For example, research has 
shown that levels of soluble TREM2 (sTREM2) in CSF are 
increased in familial FTD cases carrying mutations in the 
progranulin gene (GRN) compared to controls [83]. Like-
wise, a C9orf72-deficient mouse showed increased expres-
sion of Trem2, C1qa, and Tyrobp linking decreased expres-
sion of C9orf72 with microglia activity and age-related 
neuroinflammation [43]. As with GRN and C9orf72, other 
FTD genes, including TANK-binding kinase 1 (TBK1), 
Optineurin (OPTN), sequestosome (SQSTM1), and Valosin 
Fig. 5  Co-regulatory network shared between APOE, TREM2, and 
PLCG2. a Venn diagram showing the number and the overlap of 
genes highly co-expressed APOE, TREM2, and PLCG2. b Depiction 
of potential relationships between genes included in the shared co-
expression network of APOE, TREM2, and PLCG2. The red circle 
marks members of the complement cascade. The green circle marks 
genes involved in tissue remodeling. Green lines between proteins 
indicate evidence for interaction based on text mining, black lines 
represent co-expression, blue lines indicate evidence from curated 
databases, and magenta lines indicate experimentally conformed 
interactions
1037Acta Neuropathologica (2020) 139:1025–1044 
1 3
Containing Protein (VCP), have been linked to neuroin-
flammation and microglial function, because these genes 
can regulate one of the crucial regulators of glial acti-
vation and neuroinflammation, the nuclear factor-kappa 
beta (NF-κβ) [22]. Importantly, NF-κβ has been shown 
to be a downstream effector of PLCG2 activation [65]. It 
is, therefore, tempting to speculate that downstream neu-
roinflammatory processes activated by protein aggrega-
tion in FTD will lead to activation of a signaling cascade 
involving PLCG2 wherein the p.P522R-carrying PLCG2 
may show its protective effect. In addition, all these find-
ings together may have uncovered a more general effect of 
PLCG2 in the response to misfolded protein aggregation 
found in neurodegenerative disorders. At this point, it is 
important to note that the reported effect of p.P522R on 
susceptibility to FTD and DLB still requires validation in 
independent samples [78].
Besides the effect downstream of Aβ1-42 pathology, 
p.P522R might also contribute to the initial formation 
and amplification of pathological protein aggregates itself 
instead of modulating their downstream effects. Herein, 
research has shown that microglia contribute to an accel-
erated formation of amyloid plaques and tau aggregation 
[4, 5, 70, 72, 85] which is probably dependent on the acti-
vation of the inflammasome [28, 73, 79]. The protective 
effect of p.P522R in PLCG2 could modulate the micro-
glial pathways leading to this accelerated pathology. Our 
results, however, do not support this hypothesis, because 
we could not find evidence for an association of p.P522R 
with  Abeta1-42 pathology or  pTau181 and tTau in amyloid-
negative individuals. Albeit a negative finding, this result 
should be interpreted with caution, because our AD-
focused study design and the limited number of amyloid-
negative MCI patients in our sample might have rendered 
our sample underpowered to detect significant effects of 
p.P522R on neurodegenerative markers in the absence of 
amyloidosis. Consequently, additional studies in samples 
enriched for non-AD dementias are now needed to test our 
observation.
Interestingly, the stronger effect of p.P552R on tau 
pathology and cognitive decline in the presence of amyloid 
pathology offers, in turn, a possible explanation for the lack 
of association between p.P522R and cognitive decline in 
population-based studies. The cognitive decline observed 
in older individuals from the general population is thought 
to derive from an increased vulnerability of the brain to 
the initiation of neurodegenerative and non-pathological 
processes [6, 18, 25, 31]. However, in populations of MCI 
patients, the prevalence of amyloid and other neuropatholo-
gies is increased and exerts a stronger effect on the cognitive 
decline as compared to cognitively unimpaired participants 
[26, 32] who form the majority of participants in population-
based studies [62]. In fact, MCI cases show a 20–30% higher 
prevalence of amyloid positivity compared to cognitively 
normal individuals, independently of age range analyzed 
[32, 63], as well as a higher prevalence of tau and Lewy 
body pathology [2]. Our line of arguments receives further 
support from the observation that the prevalence of amyloid 
and tau pathology increases with age [7] as well as the prob-
ability of being carrier of the p.P522R variant [78]. Thus, 
it is tempting to speculate that slower cognitive decline in 
MCI patients and prolonged survival of p.P522R carriers in 
older ages is due to a modulation of the neuroinflammatory 
response to progressive pathological protein aggregation, 
such as amyloid, which leads, in turn, to increased neuronal 
survival and, finally, improved cognition contributing to 
longevity [23].
We also examined the potential biological mechanisms 
underlying the observed effects of p.P522R. Given the 
compelling evidence supporting the link between TREM2 
and APOE at the molecular level, we search for potential 
shared pathways between TREM2, APOE, and PLCG2. In 
supporting this hypothesis, the three genes are involved in 
microglial response within various neurodegenerative con-
ditions. Importantly, APOE and TREM2 might be linked 
to PLCG2 at the molecular level, as APOE is a ligand of 
TREM2 [84] and TREM2 is a surface receptor upstream 
of PLCG2-signaling cascade [54]. Further supporting their 
functional connection, all three genes modulate similar AD 
endophenotypes. This includes the effect described here for 
the APOE-ε4 allele and p.P522R in PLCG2 on the cognitive 
decline. In addition, in 2019, a rare protective coding variant 
in APOE, different from the APOE-ε2 allele, was found to 
mitigate downstream effects of amyloid-beta formation [3], 
as observed for p.P522R in our study. Furthermore, similar 
to p.P522R, CSF levels of sTREM2 and the p.R47H variant 
in TREM2 are both strongly associated with tau pathology 
[46, 60]. In the case of sTREM2, its CSF levels also show 
specific alterations in amyloid positive individuals without 
tau pathology [74]. In line with these molecular and phe-
notypic links, our unsupervised trans-coregulatory network 
analysis based on microarray data from multiple tissues and 
experimental conditions suggested that APOE, PLCG2, and 
TREM2 share a common, general co-expression network. 
This network contains the AD hub-gene TYROBP [88] and 
it is highly enriched for the complement cascade and genes 
differentially expressed in microglia from AD patients [49] 
or mouse models of AD (FXFAD model; [39]) or tauopa-
thies (hMAPT -P301S model; [19]). Thus, several biological 
processes that have been identified as crucial for the patho-
genesis of AD but also other neurodegenerative dementias 
[14, 21] may not only involve APOE and TREM2, as previ-
ously described [67] but also PLCG2. Consequently, taking 
our present and previous research, it is tempting to specu-
late that this shared mechanism could include the adaption 
of microglia to a neurodegenerative environment that may 
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contribute to the protective effect across different neurode-
generative dementias, as hypothesized before. Among the 
pleiotropy of potential underlying pathways, our co-expres-
sion network analysis highlights several mechanisms. Those 
could involve altered downstream TREM2 signaling includ-
ing the co-expression network members SPP1 and GPNMB 
[44, 69]. Alternatively, those mechanisms could include the 
differential regulation of the signaling of CD14 and Toll-like 
receptors [86, 87] or complement receptors [9, 48]. Impor-
tantly, complement cascade activation is observed in several 
neurodegenerative diseases, including AD, DLB, and FTD 
[21, 80] and is strongly involved in synapse loss [27] which 
is strongly related to cognitive impairments [76]. These can-
didate pathways require further experimental investigation 
to establish a role in the mediation of the effect of p.P522R 
on AD, as well as in other neurodegenerative dementias. In 
fact, several efforts are currently ongoing to gain insight on 
the molecular mechanisms of PLCG2 variant in the immune 
pathway connecting it with other AD risk genes.
From a therapeutic point of view, PLCG2-directed thera-
peutic approaches might, therefore, offer a novel opportunity 
to complement drugs directed at amyloid clearance or pro-
duction by modulating the downstream effects of amyloid 
pathology mediated by microglia [12, 28, 51, 71]. Particular 
interest, herein, deserves the observation that the protective 
effect of p.P522R can apparently counteract the deleterious 
effect of APOE-ε4 on cognitive decline for several years and 
on tau pathology in MCI. Both effects probably derive from 
the similar effect sizes of the two genetic variants. Of note, 
APOE-ε4 showed its strongest effect on amyloid pathology 
and only a smaller but independent effect on tau pathology, 
suggesting that APOE-ε4 influences AD pathogenesis more 
upstream in the amyloid cascade than p.P522R. Thus, thera-
peutic approaches targeting PLCG2 function might comple-
ment those aiming at APOE function. However, our data 
also suggest that the buffering properties of p.P522R against 
APOE-ε4-induced deficits seem to decrease as the disease 
progresses. This reduction in effect may be produced by 
chronical exposure of microglia to deleterious insult under-
mining the protective function of microglia including the 
protective effect given by p.P522R in PLCG2. Understand-
ing the pathways underlying the protective effect of PLCG2 
and its buffering properties may help to develop therapeutic 
targets which can counteract this progressive collapse of the 
protection delaying or even preventing the beginning of the 
dementia stage.
Strength and limitations
A considerable strength of our study is the recruitment and 
analysis of one of the largest samples of MCI patients with 
longitudinal follow-up and CSF biomarkers. This data set 
offers the unique opportunity to study the effect of p.P522R 
at this disease stage and to define the link between its effects 
on clinical data and the underlying pathophysiological pro-
cess. Besides, we used an agnostic co-expression network 
analysis that does not rely on specific cell or tissue expres-
sion profile experiments that are usually based in very low 
numbers and, therefore, prone to measurement error. Impor-
tantly, using a general approach relying on a wide range 
of experiments led us to replicate the previous findings on 
expression network [10, 68, 88] and also led us to the dis-
covery of a novel links between APOE and TREM2–PLCG2 
signaling. Furthermore, the integrative analysis of bio-
marker, cognitive, and gene-expression data provides the 
most comprehensive description of the role of PLCG2 in 
AD pathogenesis to date.
However, our study has also limitations. Our results are 
based on a limited number of carriers due to the low fre-
quency of the p.P522R variant. Especially when examin-
ing the interaction of p.P522R with APOE-ε4 or Aβ1-42, the 
limited number of carriers might have rendered our study 
underpowered for quantifying the exact effect size of the 
interaction. Thus, investigations of independent samples are 
now necessary to confirm these observations. Nevertheless, 
the consistency of the effect of p.P522R across cohorts and 
phenotypes supports the robustness of our findings. Addi-
tionally, amyloid and tau burden from cognitively healthy 
individuals were not available. Since the trajectory of amy-
loid pathology is expected to reach a plateau in late disease 
stages [30], the lack of cognitively normal patients with CSF 
samples might have limited our ability to detect the effects 
of p.P522R on CSF-Aβ1-42 levels. We were, however, able to 
detect an effect for the APOE-ε4 allele. Finally, confirmation 
of findings from the co-regulatory network analysis is still 
required using microglia expression data.
In conclusion, our data link the protective effect of 
p.P522R in PLCG2 to lower CSF concentrations of  pTau181 
and tTau and slower cognitive decline in MCI patients, par-
ticularly in amyloid positive individuals and with an effect 
size similar to that of APOE. We present converging evi-
dence, suggesting that the rare variant p.P522R in PLCG2 
might reduce the effect of amyloidosis upon tau pathology 
and cognitive decline. Therapies targeting the druggable 
enzyme PLCG2 [17, 68] might, thus, provide a novel thera-
peutic approach with the potential for disease modification in 
AD might as well buffer the deleterious effect of APOE-ε4.
Acknowledgements Open Access funding provided by Projekt DEAL. 
This publication was funded in part by the German Federal Ministry of 
Education and Research (BMBF) (grants KND: 01GI0102, 01GI0420, 
01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434; 
grants KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 
01GI0715, 01GI0716, 01ET1006B). Analyses were also funded by 
the German Federal Ministry of Education and Research (BMBF 
01EA1410A) within the project “Diet-Body-Brain: from epidemiol-
ogy to evidence-based communication”. Part of the work was funded 
by the JPND EADB grant (German Federal Ministry of Education 
1039Acta Neuropathologica (2020) 139:1025–1044 
1 3
and Research (BMBF) grant: 01ED1619A). Part of the analysis was 
funded by the German Research Foundation (DFG) grant: RA 1971/6-1 
to Alfredo Ramirez. Research of the Alzheimer Center Amsterdam is 
part of the neurodegeneration research program of Amsterdam Neuro-
science. The Alzheimer Center Amsterdam is supported by Stichting 
Alzheimer Nederland and Stichting VUmc fonds. The clinical database 
structure was developed with funding from Stichting Dioraphte. Geno-
typing of the Dutch case–control samples was performed in the context 
of EADB (European Alzheimer DNA biobank) funded by the JPco-
fuND FP-829-029 (ZonMW project number 733051061). Data collec-
tion and sharing for this project were funded by the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) (National Institutes of Health Grant 
U01 AG024904) and DOD ADNI (Department of Defense award num-
ber W81XWH-12-2-0012). ADNI is funded by the National Institute on 
Aging, the National Institute of Biomedical Imaging and Bioengineer-
ing, and through generous contributions from the following: AbbVie, 
Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; 
Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Com-
pany; CereSpir, Inc.; Cogstate; Eisai Inc.; ElanPharmaceuticals, Inc.; Eli 
Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its 
affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO 
Ltd.; Janssen Alzheimer Immunotherapy Research and Development, 
LLC.; Johnson and Johnson Pharmaceutical Research and Development 
LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnos-
tics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Phar-
maceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda 
Pharmaceutical Company; and transition Therapeutics. The Canadian 
Institutes of Health Research is providing funds to support ADNI clini-
cal sites in Canada. Private sector contributions are facilitated by the 
Foundation for the National Institutes of Health (www.fnih.org). The 
grantee organization is the Northern California Institute for Research 
and Education, and the study is coordinated by the Alzheimer’s Thera-
peutic Research Institute at the University of Southern California. ADNI 
data are disseminated by the Laboratory for NeuroImaging at the Uni-
versity of Southern California. The Three-City Study genotyping and 
analysis was funded by the GENMED Labex, the Joint Programming 
Initiative on Neurodegenerative Diseases Research (JPND; PERADES 
project), the Institute Pasteur de Lille, the University of Lille, and the 
Nord-Pas de Calais Regional Council. This work also benefited from 
the Lille Métropole Communauté Urbaine Council, the French gov-
ernment’s LABEX DISTALZ program (development of innovative 
strategies for a transdisciplinary approach to Alzheimer’s disease). In 
addition, the Three-City Study was performed as part of a collaboration 
between the Institut National de la Santé et de la Recherche Médicale 
(Inserm), the Victor Segalen Bordeaux II University and Sanofi-Syn-
thélabo. The Fondation pour la Recherche Médicale funded the prepa-
ration and initiation of the study. Additional funding for the 3C Study 
was also obtained from the Caisse Nationale Maladie des Travailleurs 
Salariés, Direction Générale de la Santé, MGEN, Institut de la Lon-
gévité, Agence Française de Sécurité Sanitaire des Produits de Santé, 
the Aquitaine and Bourgogne Regional Councils, Fondation de France 
and the joint French Ministry of Research/INSERM “Cohortes et collec-
tions de données biologiques” programme. Lille Génopôle received an 
unconditional grant from Eisai. Fundacio ACE cohort receives support 
from the Innovative Medicines Initiative 2 Joint Undertaking which 
receives support from the European Union’s Horizon 2020 research 
and innovation programme (ADAPTED Grant No. 115975). A. Ruiz’s 
research is also supported by Instituto de Salud Carlos III (ISCIII) 
grants PI13/02434, PI16/01861, and PI19/01301. Acción Estratégica 
en Salud, integrated in the Spanish National R + D + I Plan and financed 
by ISCIII-Subdirección General de Evaluación and the Fondo Europeo 
de Desarrollo Regional (FEDER-“Una manera de Hacer Europa”), by 
Fundación bancaria “La Caixa” and Grifols SA (GR@ACE project). For 
the Longitudinal Aging Study Amsterdam (LASA) supports was largely 
obtained from a grant from the Netherlands Ministry of Health, Wel-
fare and Sports, Directorate of Long-Term Care. The data collection in 
2012–2013 was financially supported by the Netherlands Organization 
for Scientific Research (NWO) in the framework of the project “New 
Cohorts of young old in the twenty-first century” (File Number 480-
10-014). Genotyping using Axiom-NL array was financially supported 
by EMGO+ Research Institute. PL was supported by the Innovative 
Medicines Initiative Joint Undertaking under EMIF grant agreement 
no 115372, resources of which are composed of financial contribution 
from the European Union’s Seventh Framework Programme (FP7/2007-
2013) and EFPIA companies in kind contribution. JW is supported by 
an Ilídio Pinho professorship and iBiMED (UID/BIM/04501/2013), at 
the University of Aveiro, Portugal. JP was supported by a grant from the 
Swiss National Science Foundation (320030L_141179).
Data used in preparation of this article were obtained from the Alz-
heimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.
usc.edu). As such, the investigators within the ADNI contributed to 
the design and implementation of ADNI and/or provided data, but did 
not participate in analysis or writing of this report. A complete list-
ing of ADNI investigators can be found at: https ://adni.loni.usc.edu/
wp-2cont ent/uploa ds/how_to_apply /ADNI_Ackno wledg ement _List.
pdf. Addresses: Luca Kleineidam, Ilker Karaca, Michael T. Heneka, 
Wolfgang Maier, Anja Schneider, Michael Wagner—Universitätk-
linikum Bonn, Klinik für Neurodegenerative Erkankungen und Ger-
ontopsychiatrie, Sigmund-Freud-Straße 25, 53127 Bonn, Germany; 
Vincent Chouraki, Phillipe Amouyel, Jean-Charles Lambert—Univ. 
Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-
Facteurs de risque et déterminants moléculaires des maladies liées 
au vieillissement, F-59000 Lille 59019 France; Tomasz Próchnicki, 
Eicke Latz—Institute of Innate Immunity, Universitätklinikum Bonn, 
Sigmund-Freud-Straße 25, 53127 Bonn, Germany; Sven J. van der 
Lee, Iris E. Jansen, Marc Hulsman, Philip Scheltens, Wiesje M van der 
Flier, Henne Holstege—Alzheimer Center Amsterdam, Department of 
Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 
Amsterdam UMC, De Boelelaan 1117, 1081 HV, Amsterdam, The 
Netherlands; Laura Madrid-Márquez, Antonio González-Pérez, Mª 
Eugenia Sáez—Andalusian Bioinformatics Research Centre (CAEBi), 
Río de la Plata 2, Bajo 4, 41013 Seville, Spain; Holger Wagner-Thelen, 
Pamela V. Martino Adami, Frank Jessen, Alfredo Ramirez—Uni-
versitätklinik Köln, Klinik für Psychiatrie und Psychtherapie, Ker-
pener Strasse 62, 50937 Köln, Germany; Leonie Weinhold, Matthias 
Schmid—Institute of Medical Biometry, Informatics and Epidemi-
ology (IMBIE), Universitätklinikum Bonn, Sigmund-Freud-Str. 25, 
53127, Bonn, Germany; Steffen Wolfsgruber, Frederic Brosseron—
German Center for Neurodegenerative Diseases (DZNE), Sigmund-
Freud-Straße 27, 53127 Bonn, Germany; Anne Boland, Jean-Francois 
Deleuze—Centre National de Recherche en Génomique Humaine, CP 
5721, 2 rue Gaston Crémieux, 91057 EVRY Cedex; Piotr Lewczuk, 
Johannes Kornhuber—Universitätsklinikum Erlangen, Psychiatrische 
und Psychotherapeutische Klinik, Schwabachanlage 6, 91054 Erlan-
gen, Germany; Julius Popp—Department of Psychiatry, Lausanne 
University Hospital, Route du Mont, 1008, Prilly, Switzerland; Oliver 
Peters—Charité-Universitätsmedizin Berlin, Klinik für Psychiatrie und 
Psychtherapie, Hindenburgdamm 30, 12203 Berlin, Germany; Claudine 
Berr—Inserm U1061, Hôpital La Colombière, 39 av. Charles Flahault, 
B.P. 34493, 34093 Montpellier Cedex 5, France; Reinhard Heun—
Universtitätklinikum Bonn, Klinik für Psychiatrie und Psychotherapie, 
Sigmund-Freud-Straße 25, 53127 Bonn, Germany; Lutz Frölich—Zen-
tralinstitut für Seelische Gesundheit (ZI), Quadrat J5, 68159 Man-
nheim, Germany; Christophe Tzourio, Jean-François Dartigues—Bor-
deaux Population Health (BPH Center), INSERM U1219, Université 
de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux cedex; Michael 
Hüll—Zentrum für Psychiatrie Emmendingen, Klinik für Alterspsy-
chiatrie- und psychotherapie, Neubronnstr. 25, 79312 Emmendingen, 
Germany; Ana Espinosa, Isabel Hernández, Itziar de Rojas, Adelina 
Orellana, Sergi Valero, Agustin Ruiz, Lluis Tarraga, Merce Boada—
Research Center and Memory Clinic. Fundació ACE. Institut Català 
de Neurociències Aplicades-Universitat Internacional de Catalunya 
1040 Acta Neuropathologica (2020) 139:1025–1044
1 3
– Barcelona, Gran Via de Carles IIII. 85bis. 08028, Barcelona, Spain; 
Najada Stringa, Natasja M. van Schoor, Martijn Huisman—Amster-
dam Public Health Research Institute, Department of Epidemiology 
and Biostatistics, Amsterdam UMC – Vrije Universiteit Amsterdam, 
De Boelelaan 1089A, 1081 HV, Amsterdam, the Netherlands; Eckart 
Rüther, Jens Wiltfang—Universitätmedizin Göttingen, Klinik für Psy-
chiatrie und Psychotherapie, Von-Siebold-Straße 5, 37075 Göttingen, 
Germany; Martin Scherer—Institut für Allgemeinmedizin, Universität-
sklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg; 
Steffi Riedel-Heller—Institut für Sozialmedizin, Arbeitsmedizin und 
Public Health (ISAP), Medizinische Fakultät, Universität Leipzig, Ph.-
Rosenthal-Str. 55, 04103 Leipzig, Germany.
Author contributions LK designed and conceptualized the study, ana-
lyzed and interpreted the data, and drafted the manuscript. VC con-
tributed to the design of the study, analyzed the longitudinal data from 
the 3C study, and interpreted the data. SvdL contributed to the design 
of the study, analyzed the longitudinal data from the LASA cohort, 
and interpreted the data. LM-M contributed to the design, acquisi-
tion, and analysis of gene co-expression data, and interpreted the data. 
HWT contributed to the analysis of CSF biomarkers, data acquisition, 
and interpretation. TP, IK, LW, SW, MS, and AG-P contributed to the 
design of the study and interpreted the data. AB, PVMA, PL, JP, FB, 
IJ, MH, AE, IH, IR, AO, SV, NS, NMS, PA, J-FDe, and AS contributed 
to the data acquisition. JK, CB, LF, OP, CT, J-FDa, MHül, MHui, PS, 
ER, JW, RH, LT, MS, SR-H, MTH, MB, WM, and WMF contributed 
to the design of the study and data acquisition. MW, FJ, J-CL, HH, 
MES, and EL contributed the design, acquisition, and interpretation 
of the data. AR designed and conceptualized the study, contributed to 
the acquisition of data, interpreted the data, conducted the gene co-
expression analyses, and contributed to the writing of the manuscript. 
AR supervised the study, wrote the manuscript, designed and concep-
tualized the study, and acquired and interpreted the data. All authors 
critically revised the manuscript for important intellectual content and 
approved the final manuscript.
Compliance with ethical standards 
Conflict of interest All authors report no conflict of interest. Piotr 
Lewczuk received a consultation and/or lecture honoraria from IBL 
International, Fujirebio Europe, AJ Roboscreen, and Roche. Jens Wilt-
fang received honoraria for consulting activities, lectures or advisory 
board participation from Pfizer, Eli Lilly, Hoffmann-La-Roche, MSD 
Sharp + Dome, Janssen-Cilag GmbH, Immungenetics AG, Boehringer 
Ingelheim. Lutz Frölich received honoraria for consulting activities, 
lectures, or advisory board participation from Allergan, Eli Lilly, 
Avraham Pharmaceuticals, Axon Neuroscience, Axovant, Biogen, 
Boehringer Ingelheim, Eisai, Functional Neuromodulation, Lund-
beck, MerckSharpe and Dohme, Novartis, Pfizer, Pharnext, Roche, 
Schwabe Pharma; he served on Data and Safety Monitoring boards or 
endpoint committees with Avraham Pharmaceuticals, Axon Neurosci-
ence, Forschungszentrum Jülich, Novartis, Pharmatropix. Julius Popp 
received honoraria for consulting activities, lectures or advisory board 
participation from Fujirebio Europe, Ono Pharma, Eli Lilly, and Nestlé 
Institute of Health Sciences. Agustin Ruiz reports consulting Fees: 
Landsteiner Genmed, Grifols, Araclon biotech. And Lecture Fees: 
Araclon Biotech.PA reports personal fees from Servier, Total, Geno-
screen, Takeda, and Foundation Alzheimer. Oliver Peters received re-
search funding, consultancy fees, or speech honoraria from Axovant, 
Biogen, Genentech, Lilly, Lundbeck, Novartis, Pharmatrophix, Pira-
mal, Probiodrug, Roche, Takeda, and TauRx Pharmaceuticals. Merce 
Boada receives fees or has received for consulting from Lab. Servier, 
Roche, Lilly, Avid, Bayer, Elan, Janssen, Neuroptix, and Sanofi. She 
receives or has received fees for lectures from Lilly, Nutricia, Roche, 
Schwabe, Araclon, Esteve, Grifols, Janssen, Novartis, Piramal, Pfizer-
Wyett, and Servier. She receives fees for being part of the Advisory 
Board of Lilly and Schwabe. She reports grants/research funding from 
Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, 
S.A, Merck Sharp and Dohme, Kyowa Hakko Kirin, Laboratorios 
Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, 
Roche Pharma SA, and Schwabe Farma iberica SLU, all outside the 
submitted work. She has not received personal compensations from 
these organizations.
Ethical approval All procedures performed in studies involving human 
participants were following the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declara-
tion and its later amendments or comparable ethical standards. For this 
retrospective study, all patients’ clinical, genetic, and biomarker data 
were already available at the time point of this study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Abdelnour C, van Steenoven I, Londos E et al (2016) Alzhei-
mer’s disease cerebrospinal fluid biomarkers predict cognitive 
decline in lewy body dementia. Mov Disord 31(8):1203–1208
 2. Abner EL, Kryscio RJ, Schmitt FA et  al (2017) Outcomes 
after diagnosis of mild cognitive impairment in a large autopsy 
series. Ann Neurol 81(4):549–559
 3. Arboleda-Velasquez JF, Lopera F, O’Hare M et  al (2019) 
Resistance to autosomal dominant Alzheimer’s disease in an 
APOE3 Christchurch homozygote: a case report. Nat Med 
25(11):1680–1683
 4. Asai H, Ikezu S, Tsunoda S et al (2015) Depletion of microglia 
and inhibition of exosome synthesis halt tau propagation. Nat 
Neurosci 18(11):1584–1593
 5. Bhaskar K, Konerth M, Kokiko-Cochran ON et al (2010) Regu-
lation of tau pathology by the microglial fractalkine receptor. 
Neuron 68(1):19–31
 6. Boyle PA, Wilson RS, Yu L et al (2013) Much of late life cogni-
tive decline is not due to common neurodegenerative patholo-
gies. Ann Neurol 74(3):478–489
 7. Braak H, Thal DR, Ghebremedhin E et al (2011) Stages of the 
pathologic process in Alzheimer disease: age categories from 1 
to 100 years. J Neuropathol Exp Neurol 70(11):960–969
 8. Chae JJ, Park YH, Park C et al (2015) Brief report: connecting 
two pathways through  Ca2+ signaling: NLRP3 inflammasome 
activation induced by a hypermorphic PLCG2 mutation. Arthri-
tis Rheumatol 67(2):563–567
 9. Cohen G, Makranz C, Spira M et al (2006) Non-PKC DAG/
Phorbol-Ester receptor (s) inhibit complement receptor-3 and 
nPKC inhibit scavenger receptor-AI/II-mediated myelin phago-
cytosis but cPKC, PI3k, and PLCγ activate myelin phagocytosis 
by both. Glia 53(5):538–550
1041Acta Neuropathologica (2020) 139:1025–1044 
1 3
 10. Conway OJ, Carrasquillo MM, Wang X et al (2018) ABI3 and 
PLCG2 missense variants as risk factors for neurodegenerative 
diseases in Caucasians and African Americans. Mol Neurode-
gener 13(1):53
 11. Curran PJ, Hussong AM (2009) Integrative data analysis: the 
simultaneous analysis of multiple data sets. Psychol Methods 
14(2):81
 12. Dagher NN, Najafi AR, Kayala KMN et al (2015) Colony-stim-
ulating factor 1 receptor inhibition prevents microglial plaque 
association and improves cognition in 3xTg-AD mice. J Neuro-
inflamm 12(1):139
 13. Dalmasso MC, Brusco LI, Olivar N et al (2019) Transethnic 
meta-analysis of rare coding variants in PLCG2, ABI3, and 
TREM2 supports their general contribution to Alzheimer’s 
disease. Transl Psychiatry 9(1):55
 14. Deczkowska A, Keren-Shaul H, Weiner A et al (2018) Disease-
associated microglia: a universal immune sensor of neurodegen-
eration. Cell 173(5):1073–1081
 15. Enders CK (2010) Applied missing data analysis. Guilford 
Press, New York
 16. Ferrari R, Wang Y, Vandrovcova J et al (2017) Genetic archi-
tecture of sporadic frontotemporal dementia and overlap with 
Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psy-
chiatry 88(2):152–164
 17. Finan C, Gaulton A, Kruger FA et al (2017) The druggable 
genome and support for target identification and validation in 
drug development. Sci Transl Med 9(383):eaag1166
 18. Fjell AM, McEvoy L, Holland D et al (2014) What is normal 
in normal aging? Effects of aging, amyloid and Alzheimer’s 
disease on the cerebral cortex and the hippocampus. Prog Neu-
robiol 117:20–40
 19. Friedman BA, Srinivasan K, Ayalon G et al (2018) Diverse brain 
myeloid expression profiles reveal distinct microglial activation 
states and aspects of Alzheimer’s disease not evident in mouse 
models. Cell Rep 22(3):832–847
 20. Guerreiro RJ, Lohmann E, Brás JM et al (2013) Using exome 
sequencing to reveal mutations in TREM2 presenting as a fron-
totemporal dementia–like syndrome without bone involvement. 
JAMA Neurol 70(1):78–84
 21. Hammond TR, Marsh SE, Stevens B (2019) Immune signaling in 
neurodegeneration. Immunity 50(4):955–974
 22. Haukedal H, Freude K (2019) Implications of microglia in amyo-
trophic lateral sclerosis and frontotemporal dementia. J Mol Biol 
431(9):1818–1829
 23. Hayat SA, Luben R, Dalzell N et al (2018) Understanding the 
relationship between cognition and death: a within cohort exami-
nation of cognitive measures and mortality. Eur J Epidemiol 
33(11):1049–1062
 24. Heckman MG, Kasanuki K, Brennan RR et al (2019) Association 
of MAPT H1 subhaplotypes with neuropathology of lewy body 
disease. Mov Disord 34:1325–1332
 25. Herrup K (2010) Reimagining Alzheimer’s disease—an age-based 
hypothesis. J Neurosci 30(50):16755–16762
 26. Hohman TJ, Tommet D, Marks S et al (2017) Evaluating Alzhei-
mer’s disease biomarkers as mediators of age-related cognitive 
decline. Neurobiol Aging 58:120–128
 27. Hong S, Beja-Glasser VF, Nfonoyim BM et al (2016) Comple-
ment and microglia mediate early synapse loss in Alzheimer 
mouse models. Science 352(6286):712–716
 28. Ising C, Venegas C, Zhang S et al (2019) NLRP3 inflammasome 
activation drives tau pathology. Nature 575(7784):669–673
 29. Jack R Jr, Clifford, Bennett DA, Blennow K et al (2018) NIA-AA 
research framework: toward a biological definition of Alzheimer’s 
disease. Alzheimers Dement 14(4):535–562
 30. Jack CR Jr, Clifford R, Knopman DS, Jagust WJ et al (2013) 
Tracking pathophysiological processes in Alzheimer’s disease: 
an updated hypothetical model of dynamic biomarkers. Lancet 
Neurol 12(2):207–216
 31. Jagust W (2013) Vulnerable neural systems and the borderland of 
brain aging and neurodegeneration. Neuron 77(2):219–234
 32. Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of 
cerebral amyloid pathology in persons without dementia: a meta-
analysis. Jama 313(19):1924–1938
 33. Jansen IE, Savage JE, Watanabe K et al (2019) Genome-wide 
meta-analysis identifies new loci and functional pathways influ-
encing Alzheimer’s disease risk. Nat Genet 51:404–413
 34. Jay TR, von Saucken VE, Landreth GE (2017) TREM2 in neuro-
degenerative diseases. Mol Neurodegener 12(1):56
 35. Jones L, Lambert J-C, Wang L-S et al (2015) Convergent genetic 
and expression data implicate immunity in Alzheimer’s disease. 
Alzheimers Dement 11(6):658–671
 36. Jun G, Ibrahim-Verbaas CA, Vronskaya M et al (2016) A novel 
Alzheimer disease locus located near the gene encoding tau pro-
tein. Mol Psychiatry 21(1):108
 37. Kamb A, Harper S, Stefansson K (2013) Human genetics as a 
foundation for innovative drug development. Nat Biotechnol 
31(11):975
 38. Karran E, Mercken M, de Strooper B (2011) The amyloid cascade 
hypothesis for Alzheimer’s disease: an appraisal for the develop-
ment of therapeutics. Nat Rev Drug Discov 10(9):698
 39. Keren-Shaul H, Spinrad A, Weiner A et al (2017) A unique micro-
glia type associated with restricting development of Alzheimer’s 
disease. Cell 169(7):1276–1290
 40. Koller M, Stahel WA (2017) Nonsingular subsampling for 
regression S estimators with categorical predictors. Comput Stat 
32(2):631–646
 41. Kunkle BW, Grenier-Boley B, Sims R et al (2019) Genetic meta-
analysis of diagnosed Alzheimer’s disease identifies new risk loci 
and implicates Aβ, tau, immunity and lipid processing. Nat Genet 
51(3):414–430
 42. Lacour A, Espinosa A, Louwersheimer E et al (2017) Genome-
wide significant risk factors for Alzheimer’s disease: role in pro-
gression to dementia due to Alzheimer’s disease among subjects 
with mild cognitive impairment. Mol Psychiatry 22(1):153
 43. Lall D, Baloh RH (2017) Microglia and C9orf72 in neuroin-
flammation and ALS and frontotemporal dementia. J Clin Invest 
127(9):3250–3258
 44. Lee CD, Daggett A, Gu X et al (2018) Elevated TREM2 gene 
dosage reprograms microglia responsivity and ameliorates 
pathological phenotypes in Alzheimer’s disease models. Neuron 
97(5):1032–1048
 45. Liao Y, Wang J, Jaehnig EJ et al (2019) WebGestalt 2019: gene 
set analysis toolkit with revamped UIs and APIs. Nucleic Acids 
Res 47(W1):W100–W205
 46. Lill CM, Rengmark A, Pihlstrøm L et  al (2015) The role of 
TREM2 R47H as a risk factor for Alzheimer’s disease, fronto-
temporal lobar degeneration, amyotrophic lateral sclerosis, and 
Parkinson’s disease. Alzheimers Dement 11(12):1407–1416
 47. Magno L, Lessard CB, Martins M et al (2019) Alzheimer’s dis-
ease phospholipase C-gamma-2 (PLCG2) protective variant is a 
functional hypermorph. Alzheimers Res Ther 11(1):16
 48. Makranz C, Cohen G, Baron A et al (2004) Phosphatidylinositol 
3-kinase, phosphoinositide-specific phospholipase-Cγ and protein 
kinase-C signal myelin phagocytosis mediated by complement 
receptor-3 alone and combined with scavenger receptor-AI/II in 
macrophages. Neurobiol Dis 15(2):279–286
 49. Mathys H, Davila-Velderrain J, Peng Z et  al (2019) Single-
cell transcriptomic analysis of Alzheimer’s disease. Nature 
570(7761):332–337
 50. Muthén LK, Muthén BO (1998–2012). Mplus user’s guide, 7th 
Edn. Muthén & Muthén, Los Angeles, CA
1042 Acta Neuropathologica (2020) 139:1025–1044
1 3
 51. Olmos-Alonso A, Schetters STT, Sri S et al (2016) Pharmaco-
logical targeting of CSF1R inhibits microglial proliferation and 
prevents the progression of Alzheimer’s-like pathology. Brain 
139(3):891–907
 52. Ombrello MJ, Remmers EF, Sun G et al (2012) Cold urticaria, 
immunodeficiency, and autoimmunity related to PLCG2 deletions. 
N Engl J Med 366(4):330–338
 53. Ossenkoppele R, Jansen WJ, Rabinovici GD et al (2015) Preva-
lence of amyloid PET positivity in dementia syndromes: a meta-
analysis. Jama 313(19):1939–1950
 54. Peng Q, Malhotra S, Torchia JA et al (2010) TREM2-and DAP12-
dependent activation of PI3K requires DAP10 and is inhibited by 
SHIP1. Sci Signal 3(122):ra38–ra38
 55. Plenge RM, Scolnick EM, Altshuler D (2013) Validating ther-
apeutic targets through human genetics. Nat Rev Drug Discov 
12(8):581
 56. Proust-Lima C, Dartigues J-F, Jacqmin-Gadda H (2011) Misuse of 
the linear mixed model when evaluating risk factors of cognitive 
decline. Am J Epidemiol 174(9):1077–1088
 57. Proust-Lima C, Philipps V, Liquet B (2017) Estimation of 
extended mixed models using latent classes and latent pro-
cesses: The R package lcmm. J Stat Softw 78(2):56. https ://doi.
org/10.18637 /jss.v078.i02
 58. R Core Team (2018) R: a language and environment for statisti-
cal computing. R Foundation for Statistical Computing, Vienna. 
http://www.R-proje ct.org
 59. Raghavan N, Samtani MN, Farnum M et al (2013) The ADAS-
Cog revisited: novel composite scales based on ADAS-Cog 
to improve efficiency in MCI and early AD trials. Alzheimers 
Dement 9(1):S21–S31
 60. Rauchmann B-S, Schneider-Axmann T, Alexopoulos P et al (2019) 
CSF soluble TREM2 as a measure of immune response along the 
Alzheimer’s disease continuum. Neurobiol Aging 74:182–190
 61. Rayaprolu S, Mullen B, Baker M et al (2013) TREM2 in neuro-
degeneration: evidence for association of the p R47H variant with 
frontotemporal dementia and Parkinson’s disease. Mol Neurode-
gener 8(1):19
 62. Roberts R, Knopman DS (2013) Classification and epidemiology 
of MCI. Clin Geriatr Med 29(4):753–772
 63. Roberts RO, Aakre JA, Kremers WK et al (2018) Prevalence and 
outcomes of amyloid positivity among persons without demen-
tia in a longitudinal, population-based setting. JAMA Neurol 
75(8):970–979
 64. Rongve A, Witoelar A, Ruiz A et al (2019) GBA and APOE ε4 
associate with sporadic dementia with Lewy bodies in European 
genome wide association study. Sci Rep 9(1):7013
 65. Schulze-Luehrmann J, Ghosh S (2006) Antigen-receptor signaling 
to nuclear factor κB. Immunity 25(5):701–715
 66. Shen M-Y, Hsiao G, Fong T-H et al (2008) Expression of amyloid 
beta peptide in human platelets: pivotal role of the phospholipase 
Cγ2-protein kinase C pathway in platelet activation. Pharmacol 
Res 57(2):151–158
 67. Shi Y, Holtzman DM (2018) Interplay between innate immunity 
and Alzheimer disease: APOE and TREM2 in the spotlight. Nat 
Rev Immunol 18(12):759–772
 68. Sims R, van der Lee SJ, Naj AC et al (2017) Rare coding vari-
ants in PLCG2, ABI3, and TREM2 implicate microglial-mediated 
innate immunity in Alzheimer’s disease. Nat Genet 49(9):1373
 69. Song WM, Joshita S, Zhou Y et al (2018) Humanized TREM2 
mice reveal microglia-intrinsic and-extrinsic effects of R47H 
polymorphism. J Exp Med 215(3):745–760
 70. Sosna J, Philipp S, Albay R et al (2018) Early long-term admin-
istration of the CSF1R inhibitor PLX3397 ablates microglia and 
reduces accumulation of intraneuronal amyloid, neuritic plaque 
deposition and pre-fibrillar oligomers in 5XFAD mouse model of 
Alzheimer’s disease. Mol Neurodegener 13(1):11
 71. Spangenberg EE, Lee RJ, Najafi AR et al (2016) Eliminating 
microglia in Alzheimer’s mice prevents neuronal loss without 
modulating amyloid-β pathology. Brain 139(4):1265–1281
 72. Spangenberg E, Severson PL, Hohsfield LA et al (2019) Sustained 
microglial depletion with CSF1R inhibitor impairs parenchymal 
plaque development in an Alzheimer’s disease model. Nat Com-
mun 10(1):1–21
 73. Stancu I-C, Cremers N, Vanrusselt H et al (2019) Aggregated Tau 
activates NLRP3–ASC inflammasome exacerbating exogenously 
seeded and non-exogenously seeded Tau pathology in vivo. Acta 
Neuropathol 137(4):599–617
 74. Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G et al 
(2019) Early increase of CSF sTREM2 in Alzheimer’s disease 
is associated with tau related-neurodegeneration but not with 
amyloid-β pathology. Mol Neurodegener 14(1):1
 75. Szklarczyk D, Gable AL, Lyon D et al (2018) STRING v11: 
protein–protein association networks with increased coverage, 
supporting functional discovery in genome-wide experimental 
datasets. Nucleic Acids Res 47(D1):D607–D613
 76. Terry RD, Masliah E, Salmon DP et al (1991) Physical basis 
of cognitive alterations in Alzheimer’s disease: synapse loss 
is the major correlate of cognitive impairment. Ann Neurol 
30(4):572–580
 77. van Dam S, Cordeiro R, Craig T et al (2012) GeneFriends: an 
online co-expression analysis tool to identify novel gene targets 
for aging and complex diseases. BMC Genom 13(1):535
 78. van der Lee SJ, Conway OJ, Jansen I et al (2019) A nonsynony-
mous mutation in PLCG2 reduces the risk of Alzheimer’s disease, 
dementia with Lewy bodies and frontotemporal dementia, and 
increases the likelihood of longevity. Acta neuropathol 138:1–14
 79. Venegas C, Kumar S, Franklin BS et al (2017) Microglia-derived 
ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature 
552(7685):355–361
 80. Waegaert R, Dirrig-Grosch S, Parisot F et al (2020) Longitudinal 
transcriptomic analysis of altered pathways in a CHMP2Bintron5-
based model of ALS-FTD. Neurobiol Dis 136:104710
 81. Wood SN (2003) Thin plate regression splines. J R Stat Soc Series 
B Stat Methodol 65(1):95–114
 82. Wood SN (2011) Fast stable restricted maximum likelihood and 
marginal likelihood estimation of semiparametric generalized lin-
ear models. J R Stat Soc Series B Stat Methodol 73(1):3–36
 83. Woollacott IOC, Nicholas JM, Heslegrave A et al (2018) Cerebro-
spinal fluid soluble TREM2 levels in frontotemporal dementia 
differ by genetic and pathological subgroup. Alzheimers Res Ther 
10(1):79
 84. Yeh FL, Wang Y, Tom I et al (2016) TREM2 binds to apolipo-
proteins, including APOE and CLU/APOJ, and thereby facilitates 
uptake of amyloid-beta by microglia. Neuron 91(2):328–340
 85. Yoshiyama Y, Higuchi M, Zhang B et al (2007) Synapse loss and 
microglial activation precede tangles in a P301S tauopathy mouse 
model. Neuron 53(3):337–351
 86. Zanoni I, Ostuni R, Marek LR et al (2011) CD14 controls the LPS-
induced endocytosis of Toll-like receptor 4. Cell 147(4):868–880
 87. Zanoni I, Tan Y, Di Gioia M et al (2017) By capturing inflamma-
tory lipids released from dying cells, the receptor CD14 induces 
inflammasome-dependent phagocyte hyperactivation. Immunity 
47(4):697–709
 88. Zhang B, Gaiteri C, Bodea L-G et al (2013) Integrated systems 
approach identifies genetic nodes and networks in late-onset Alz-
heimer’s disease. Cell 153(3):707–720
 89. Zhou HH, Singh V, Johnson SC et al (2018) Statistical tests and 
identifiability conditions for pooling and analyzing multisite data-
sets. Proc Natl Acad Sci 115(7):1481–1486
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
1043Acta Neuropathologica (2020) 139:1025–1044 
1 3
Affiliations
Luca Kleineidam1,2,3 · Vincent Chouraki4,5 · Tomasz Próchnicki6 · Sven J. van der Lee7,8 · Laura Madrid‑Márquez9 · 
Holger Wagner‑Thelen1,2 · Ilker Karaca1 · Leonie Weinhold10 · Steffen Wolfsgruber1,3 · Anne Boland11 · 
Pamela V. Martino Adami2 · Piotr Lewczuk12,13,33 · Julius Popp14,15 · Frederic Brosseron1,3 · Iris E. Jansen7,34 · 
Marc Hulsman7,8 · Johannes Kornhuber12 · Oliver Peters16,35 · Claudine Berr17 · Reinhard Heun18 · Lutz Frölich19 · 
Christophe Tzourio20 · Jean‑François Dartigues20 · Michael Hüll21 · Ana Espinosa22,23 · Isabel Hernández22,23 · 
Itziar de Rojas22,23 · Adelina Orellana22 · Sergi Valero22,23 · Najada Stringa24 · Natasja M. van Schoor24 · 
Martijn Huisman24 · Philip Scheltens7 · Alzheimer’s Disease Neuroimaging Initiative (ADNI) · Eckart Rüther25 · 
Jean‑Francois Deleuze11 · Jens Wiltfang25,26,27 · Lluis Tarraga22,23 · Matthias Schmid3,10 · Martin Scherer28 · 
Steffi Riedel‑Heller29 · Michael T. Heneka1,3,30 · Philippe Amouyel4 · Frank Jessen3,31 · Merce Boada22,23 · 
Wolfgang Maier1,3 · Anja Schneider1,3 · Antonio González‑Pérez9 · Wiesje M. van der Flier7 · Michael Wagner1,3 · 
Jean‑Charles Lambert4 · Henne Holstege7,8 · Mª Eugenia Sáez9 · Eicke Latz3,6,30,32 · Agustin Ruiz22,23 · 
Alfredo Ramirez1,2 
 * Alfredo Ramirez 
 alfredo.ramirez@uk-koeln.de
1 Department of Neurodegenerative Diseases and Geriatric 
Psychiatry, University Hospital Bonn, Bonn, Germany
2 Division of Neurogenetics and Molecular Psychiatry, 
Department of Psychiatry and Psychotherapy, Medical 
Faculty, University of Cologne, Cologne, Germany
3 German Center for Neurodegenerative Diseases (DZNE), 
Bonn, Germany
4 Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, 
U1167-RID-AGE-Facteurs de risque Et déterminants 
moléculaires des maladies liées au vieillissement, Lille, 
France
5 Epidemiology and Public Health Department, Centre 
Hospitalier Universitaire de Lille, Lille, France
6 Institute of Innate Immunity, University Hospitals Bonn, 
Bonn, Germany
7 Department of Neurology, Alzheimer Center Amsterdam, 
Amsterdam Neuroscience, Amsterdam UMC, Vrije 
Universiteit Amsterdam, Amsterdam, The Netherlands
8 Department of Clinical Genetics, Amsterdam Neuroscience, 
Amsterdam UMC, Vrije Universiteit Amsterdam, 
Amsterdam, The Netherlands
9 Andalusian Bioinformatics Research Centre (CAEBi), 
Seville, Spain
10 Institute of Medical Biometry, Informatics 
and Epidemiology, University Hospital of Bonn, Bonn, 
Germany
11 Centre National de Recherche en Génomique Humaine 
(CNRGH), Institut de Biologie François Jacob, CEA, 
Université Paris-Saclay, Évry, France
12 Department of Psychiatry and Psychotherapy, 
Universitätsklinikum Erlangen, and Friedrich-Alexander 
Universität Erlangen-Nürnberg, Erlangen, Germany
13 Department of Neurodegeneration Diagnostics, Medical 
University of Białystok, Białystok, Poland
14 Department of Psychiatry, Lausanne University Hospital, 
Prilly, Switzerland
15 Department of Geriatric Psychiatry, University Hospital 
of Psychiatry Zurich, Zurich, Switzerland
16 Department of Psychiatry, Charité – Universitätsmedizin 
Berlin, Berlin, Germany
17 INSERM, University Montpellier, Neuropsychiatry: 
Epidemiological and Clinical Research, Montpellier, France
18 Department of Psychiatry and Psychotherapy, University 
Hospital Bonn, 53127 Bonn, Germany
19 Department of Geriatric Psychiatry, Medical Faculty 
Mannheim, Central Institute of Mental Health, University 
of Heidelberg, Mannheim, Germany
20 Inserm, Bordeaux Population Health Research Center, 
UMR1219, University of Bordeaux, Bordeaux, France
21 Department of Psychiatry and Psychotherapy, 
Center for Psychiatry, Clinic for Geriatric Psychiatry 
and Psychotherapy Emmendingen, University of Freiburg, 
Freiburg, Germany
22 Research Center and Memory Clinic, Fundació ACE, Institut 
Català de Neurociències Aplicades-Universitat Internacional 
de Catalunya-Barcelona, Barcelona, Spain
23 Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Instituto 
de Salud Carlos III, Madrid, Spain
24 Department of Epidemiology and Biostatistics, Amsterdam 
Public Health Research Institute, Amsterdam UMC–Vrije 
Universiteit Amsterdam, Amsterdam, The Netherlands
25 Department of Psychiatry and Psychotherapy, University 
Medical Center Göttingen, Göttingen, Germany
26 German Center for Neurodegenerative Diseases (DZNE), 
Göttingen, Germany
1044 Acta Neuropathologica (2020) 139:1025–1044
1 3
27 iBiMED, Medical Sciences Department, University 
of Aveiro, Aveiro, Portugal
28 Department of Primary Medical Care, University Medical 
Center Hamburg-Eppendorf, Hamburg, Germany
29 Institute of Social Medicine, Occupational Health and Public 
Health, University of Leipzig, Leipzig, Germany
30 Division of Infectious Diseases and Immunology, 
Department of Medicine, University of Massachusetts 
Medical School, Worcester, MA, USA
31 Department of Psychiatry and Psychotherapy, Medical 
Faculty, University of Cologne, Cologne, Germany
32 Centre for Molecular Inflammation Research (CEMIR), 
Norwegian University of Science and Technology, 
Trondheim, Norway
33 Department of Biochemical Diagnostics, University Hospital 
of Białystok, Białystok, Poland
34 Department of Complex Trait Genetics, Center 
for Neurogenomics and Cognitive Research, Amsterdam 
Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, 
The Netherlands
35 DZNE, German Center for Neurodegenerative Diseases, 
Berlin, Germany
